atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
atai Life Sciences to participate in a panel discussion at the TD Cowen conference in Boston, MA on March 4, 2024, aiming to transform mental health treatment.
02/28/2024 - 05:00 PM
NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that management will participate in a panel discussion at the TD Cowen conference in Boston, MA, at 12:50pm ET on March 4, 2024.
A live audio webcast of the panel discussion will be available on the Investors section of the atai website under Events . A replay of the webcast will be available following the live event.
About atai Life Sciences
By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients.
atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life .
Contact Information Investor Contact: IR@atai.life
Media Contact: PR@atai.life
atai Life Sciences' ticker symbol is ATAI.
atai Life Sciences will participate in a panel discussion at the TD Cowen conference in Boston, MA at 12:50pm ET on March 4, 2024.
The live audio webcast of the panel discussion will be available on the Investors section of the atai website under Events.
Yes, a replay of the webcast will be available following the live event.
ATAI Rankings
#5001 Ranked by Stock Gains
ATAI Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Commercial Services, Miscellaneous Commercial Services
Country
Germany
City
Berlin
About ATAI
who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.
